Navigation Links
Soy-Based S-equol Supplement Reduces Hot Flash Frequency, Muscle And Joint Pain In U.S. Postmenopausal Women
Date:4/24/2012

t relief of hot flashes in menopausal women, based on placebo-controlled studies.

The investigators observed, after eight weeks of treatment, significant reductions occurred from the study start in the women's average daily hot flashes, the study's primary endpoint.  These reductions were comparable for all three S-equol treatment groups, 10, 20 or 40 mg, which ranged from decreases of 3.09 to 3.66 hot flashes daily, to that of the soy isoflavone group, which averaged decreases of 2.92.   The average number of daily hot flashes in all of the participants at the study start was 10.0 +/- 4.03. 

Muscle and joint pain improved significantly for both the 10 and 20 mg doses of S-equol compared with the soy isoflavones (p=0.003 and p=0.005, respectively), based on scores from the Greene Climacteric Scale (GCS), which measures 21 symptoms using 0 to 3 scale, where 0 was 'not at all,' 1 was 'a little,' 2 was 'quite a bit' and 3 was 'extremely,' to produce scores.

"These U.S. data expand on the previous studies in Japanese women and further document that a minimum daily 10 mg dose of S-equol would likely help women by both reducing the frequency of their hot flashes as well as decreasing their muscle and joint pain associated with menopause," said Jenks.

Further, for women who had more than eight hot flashes daily at the study start, both 20 and 40 mg S-equol were significantly better than the soy isoflavones in reducing hot flash frequency (p=0.045 and p=0.001, respectively), while the 10 mg S-equol dose had a strong positive trend (p=0.063), according to a sub-group analysis. This finding suggests that the S-equol supplement might be more useful for the women who have a higher frequency of hot flashes, Jenks said.

Also, more women in the 10, 20 and 40 mg S-equol groups achieved a reduction of 50 percent or more in their hot flash frequency by the study end than in
'/>"/>

SOURCE Pharmavite LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Soy-Based S-equol Supplement Reduces Metabolic Syndrome Risk Factors
2. Breast Health Study Advances Safety Profile for Soy-Based Natural S-equol Supplement Designed to Manage Menopause Symptoms
3. New Soy-Based Natural S-equol Supplement Reduces Menopausal Hot Flashes, Muscle and Joint Pain in First Study Among U.S. Women
4. New Fermented Soy Ingredient Containing S-equol Significantly Reduced Hot Flash Frequency
5. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
6. NoviPet to Present New Food Supplements for Dogs at Pet Industry Spring Trade Show
7. Anlit Enters Polish Market with New Food Supplements for Kids
8. BNA Books Announces the Publication of the 2011 Cumulative Supplement to "Pharmaceutical Law: Regulation of Research, Development, and Marketing"
9. BNA Books Announces the Publication of the 2011 Supplement to "Pharmaceutical Patent Law, Second Edition"
10. Cardium and SourceOne Global Partners Enter Into Cross-Strategic Equity Investment with Plans to Jointly Develop Nutritional Supplements and Medical Foods
11. Surgeon-Developed Vitamin Supplements to Support Optimal Surgical Healing Unveiled
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Inc. (NYSE MKT: CUR) announced that Jonathan D. ... long-term follow up data on the Phase I trial ... of amyotrophic lateral sclerosis (ALS or Lou Gehrig,s ... Symposium on ALS of the Foundation Andre-Delambre, in ... not open to the public, covered data up to ...
(Date:9/22/2014)... 22, 2014  AbbVie (NYSE: ABBV ... evaluating potential new medicines in the company,s oncology ... European Society of Medical Oncology (ESMO) Annual Congress, ... . Data being presented include results from a ... of veliparib (ABT-888), a poly (adenosine diphosphate [ADP]–ribose) ...
(Date:9/22/2014)... CAMBRIDGE, Mass. , Sept. 22, 2014  Seres ... diseases related to the human microbiome, today announced that ... one of 2014,s Fierce 15 biotechnology companies, designating it ... in the industry.  "Amid a great ... out for its focus and commitment to practical therapeutic ...
Breaking Medicine Technology:Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4Seres Health Named a "Fierce 15" Biotech Company for 2014 2
... Barry Edison announces that Barry Edison Ophthalmology in ... Pelleve® Wrinkle Reduction System, a revolutionary skin-tightening system ... uses Pelleve—an advanced radiofrequency technology—because the treatment delivers ... results. "I am proud to now offer Pelleve ...
... 22, 2012  Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. ... Phase 3 trial evaluating Nexavar ® (sorafenib) tablets ... cell lung cancer (NSCLC) whose disease progressed after two ... endpoint of improving overall survival.  An improvement in the ...
Cached Medicine Technology:New Jersey Ophthamologist Now Offers Pelleve Wrinkle Reduction Treatment 2Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 2Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 3Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 4Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 5Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival 6
(Date:9/22/2014)... York, NY (PRWEB) September 22, 2014 ... pain on the side of the hip , which ... bursitis treatment in Manhattan. This treatment is now offered at ... which is also called trochanteric bursitis, occurs when the ... a fluid-filled sac in the hip, between the iliotibial ...
(Date:9/22/2014)... The concept of a whole eye transplant seems ... grant from the U.S. Department of Defense, researchers ... Medicine hope to someday make implantation of an ... eye transplant could be a holy grail for ... of ophthalmology and grant co-recipient with colleagues at ...
(Date:9/22/2014)... New York, US (PRWEB) September 22, 2014 ... Heartbeat Experts’ perspectives on stakeholder management needs for the ... speak with Heartbeat Experts on stakeholder strategies for any ... clinically meaningful points of differentiation within an increasingly crowded ... , The impact of identifying community-based thought ...
(Date:9/22/2014)... Va. (PRWEB) September 22, 2014 ... the nation’s leading nonprofit authority on the ... healthcare information exchange, announced findings from its recent ... Health Plan Identifier (HPID) within electronic transactions adopted ... (HIPAA). WEDI conducted the survey from August 20 ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... a new AS365 N3+ Dauphin, the latest version of ... which is based at Miami Valley Hospital ... air medical transport helicopters. , “We have a lot ... Health Vice President, Emergency, Trauma, and CareFlight. “We’ve been ...
Breaking Medicine News(10 mins):Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:Looking ahead: Whole eye transplant under development 2Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3
... MDAn original and progressive report on health information ... online today, makes ground-breaking recommendations for new ... tensions that currently mar relationships between many HIT ... indemnity and error management of HIT systems. In ...
... November 11, 2010 A new study from researchers in ... more likely to undergo a screening colonoscopy than those who ... for female endoscopists seem to be common among women. In ... notion that rates of screening colonoscopy can be increased by ...
... , THURSDAY, Nov. 11 (HealthDay News) -- U.S. ... to binge-drink, smoke cigarettes or use illicit drugs, a new ... likely to abuse prescription drugs, according to the Center ... from an analysis of 2002 to 2009 data from the ...
... in French . , Montreal, November 11, 2010 ... additional cardiac test when undergoing diagnosis for potential heart problems, ... du Qubec Montral and the Montreal Heart Institute. ... Journal of Cardiopulmonary Rehabilitation and Prevention , a large sample ...
... By Jenifer Goodwin HealthDay Reporter , ... synthetic marijuana known as "K2" is sending young people ... and hallucinations, toxicologists warn. In recent months, physicians ... up in emergency rooms after smoking synthetic marijuana. Despite ...
... chemist Dr Guillaume Lessene has been awarded the Walter and ... annual general meeting in Melbourne, Australia. The $AUD150,000 ... played in shaping the Walter and Eliza Hall Institute. It ... Burgh in August at the age of 94. ...
Cached Medicine News:Health News:Fortify HIT contracts with education and ethics to protect patient safety, say informatics experts 2Health News:Fortify HIT contracts with education and ethics to protect patient safety, say informatics experts 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 2Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 4Health News:Additional cardiac testing vital for patients with anxiety and depression 2Health News:'Fake Marijuana' Users Showing Up in Emergency Rooms 2Health News:'Fake Marijuana' Users Showing Up in Emergency Rooms 3Health News:Medicinal chemist wins inaugural De Burgh Fellowship 2
... For enzyme immunoassays, designed to meet the ... and allows the user to run set ... The floating manifold on this strip washer ... at a time. Reliable, compact, and self-contained, ...
... available to handle multiple assays: ... Embla 384 Cell washer has ... optimized to avoid cell disturbance. ... and have been integrated with ...
... miniGene LW is a new plate washing system ... and 384 channel microplates with flat, V-shaped or ... 8 or 16 channel nozzle heads. Simple LCD ... An optional plate stacker is available for the ...
Space-saving counter top model,User initiated manual defrost,Standard features (see above),Internal freezing compartment,Removable half-shelf in refrigerator,Two shelves in door,UL 471 Commercial Ref...
Medicine Products: